Draft:Leaps by Bayer

Poseida Therapeutics Appoints Cynthia Collins to Board of Directors

Retrieved on: 
Monday, July 26, 2021
Life sciences, Biotechnology, Articles, Pharmacy, Biopharmaceutical, Pharmaceutical industry, United Therapeutics, Draft:Leaps by Bayer

SAN DIEGO, July 26, 2021 /PRNewswire/ --Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of biotechnology industry veteran Cynthia Collins to its Board of Directors, effective July 23, 2021.

Key Points: 
  • SAN DIEGO, July 26, 2021 /PRNewswire/ --Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of biotechnology industry veteran Cynthia Collins to its Board of Directors, effective July 23, 2021.
  • "We are excited to welcome Cindy to Poseida's Board of Directors," said Eric Ostertag, M.D., Ph.D., Chief Executive Officer of Poseida Therapeutics.
  • "As a recognized leader in cell and gene therapies and in growing innovative companies, she brings more than four decades of experience to our Board.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.

Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies

Retrieved on: 
Wednesday, July 14, 2021
Health, Manufacturing, Genetics, Other Manufacturing, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Gene therapy, Genetic engineering, Molecular biology, Draft:Leaps by Bayer, Patient Square Capital, Kriya Therapeutics, PATIENT SQUARE CAPITAL, KRIYA THERAPEUTICS

Kriya Therapeutics, Inc. , a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, today announced the closing of a $100 Million Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.

Key Points: 
  • Kriya Therapeutics, Inc. , a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, today announced the closing of a $100 Million Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
  • In recent years we have seen the promise of gene therapy become a reality for the treatment of a number of devastating diseases.
  • Kriya was formed with the mission of revolutionizing how gene therapies are designed, developed and produced by fully integrating advanced manufacturing technologies, computational tools and development capabilities within a single company.
  • Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy.

Leaps by Bayer leads USD 90 Million Series B financing in digital health company Ada Health

Retrieved on: 
Thursday, May 27, 2021
Companies, IG Farben, Economy of Germany, Industry economics), Aspirin, Bayer, Leverkusen, Ada Health, Draft:Leaps by Bayer

LEVERKUSEN,Germany, BERLIN andWHIPPANY, N.J., May 27, 2021 /PRNewswire/ -- Leaps by Bayer, the impact investment arm of Bayer AG, today announces that it has led a USD 90 million Series B investment in Berlin-based digital health company Ada Health GmbH ("Ada").

Key Points: 
  • LEVERKUSEN,Germany, BERLIN andWHIPPANY, N.J., May 27, 2021 /PRNewswire/ -- Leaps by Bayer, the impact investment arm of Bayer AG, today announces that it has led a USD 90 million Series B investment in Berlin-based digital health company Ada Health GmbH ("Ada").
  • In addition to today's announcement, Bayer and Ada Health are in discussions about entering into a longer-term strategic partnership to support the company's healthcare businesses.
  • Ada is a global health company founded by doctors, scientists and industry pioneers to create new possibilities for personal health.
  • Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of today's biggest challenges in health and agriculture.

Leaps by Bayer leads USD 90 Million Series B financing in digital health company Ada Health

Retrieved on: 
Thursday, May 27, 2021
Companies, IG Farben, Economy of Germany, Industry economics), Aspirin, Bayer, Leverkusen, Ada Health, Draft:Leaps by Bayer

LEVERKUSEN,Germany, BERLIN andWHIPPANY, N.J., May 27, 2021 /PRNewswire/ -- Leaps by Bayer, the impact investment arm of Bayer AG, today announces that it has led a USD 90 million Series B investment in Berlin-based digital health company Ada Health GmbH ("Ada").

Key Points: 
  • LEVERKUSEN,Germany, BERLIN andWHIPPANY, N.J., May 27, 2021 /PRNewswire/ -- Leaps by Bayer, the impact investment arm of Bayer AG, today announces that it has led a USD 90 million Series B investment in Berlin-based digital health company Ada Health GmbH ("Ada").
  • In addition to today's announcement, Bayer and Ada Health are in discussions about entering into a longer-term strategic partnership to support the company's healthcare businesses.
  • Ada is a global health company founded by doctors, scientists and industry pioneers to create new possibilities for personal health.
  • Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of today's biggest challenges in health and agriculture.